- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01089374
Phyllodes Tumor Partial Breast Radiation Study
A Prospective Study of Partial Breast Adjuvant Radiation Therapy After Resection of Borderline and Malignant Phyllodes Tumors
In 2008 a research study conducted by Dr. Barth involving 46 women determined that whole breast radiation therapy performed after a lumpectomy of borderline and malignant phyllodes tumors decreases rate of recurrence. None of the 46 participants developed a local recurrence.
Based on information we have learned from research studies, we recommend whole breast radiation therapy for women with malignant and borderline phyllodes tumors after they receive a lumpectomy.
New methods for delivering breast radiotherapy are being developed that allow radiation to be delivered solely to the site of the surgical resection. This is called partial breast radiation. The main advantage of partial breast radiation is that it simplifies treatment for the patient. Radiation is delivered twice a day for 5 days, rather than 5 days per week for 6 weeks. The main concern is that partial breast radiation might miss other sites of breast cancer in the breast receiving the radiation.
Evidence is accumulating from research studies that partial breast radiation therapy after surgical removal of the more common type of breast cancer, invasive ductal carcinoma, the breast results in rates of local recurrence that are comparable to those seen after whole breast radiation therapy.
In contrast to patients with invasive ductal cancers of the breast, it is very rare for patients to have phyllodes tumors that appear in more than one area of the breast. Review of research data determined that cancer recurrences seen in patients with phyllodes tumors that had undergone lumpectomies were almost always at the original tumor site. Therefore, partial breast radiation is likely to be as effective as whole breast radiation therapy after resection of malignant phyllodes tumors.
The purpose of the study is to determine what the chances are that a phyllodes tumor will recur in the breast when the breast is treated with partial breast radiation therapy after a lumpectomy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth-Hitchcock Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Histologic proof of phyllodes tumor of borderline or malignant grade, as first defined by Pietruszka and modified by Azzopardi and adopted by the World Health Organization (1,2,17):
- Borderline malignant: 5-9 mitoses/10 HPF, pushing or infiltrating margins, 2+ (moderate) stromal cellularity and atypia.
- Malignant: 10 or more mitoses / 10 HPF, predominantly infiltrating margins, usually 3+ (severe) stromal cellularity and atypia but occasionally 2+.
- The tumor has been excised with a breast-conserving resection and there is no tumor seen at any of the margins of the resection.
- No prior breast carcinoma or ductal carcinoma in situ in the ipsilateral breast. Patients with a local recurrence of a previously excised phyllodes tumor are eligible if the recurrence is in the area of the previous excision.
- No history of irradiation of the ipsilateral breast.
- No evidence of other areas worrisome for cancer on physical examination and mammography of the ipsilateral breast.
- Age >18 years.
- Informed consent.
Documentation that either:
- the patient's medical insurance company has certified that they will pay for the cost of radiation therapy treatments, or
- a letter from the patient indicating that they explicitly understand the costs of radiation therapy and that the sponsor (Principal Investigator) of this study will not be held responsible for these costs.
Exclusion Criteria:
- Histologically positive margins.
- Breast carcinoma or ductal carcinoma in situ in the ipsilateral breast.
- A history of irradiation to the ipsilateral breast.
- Pregnancy. A urine pregnancy test will be performed on each fertile premenopausal female prior to entry into the study. Patients with childbearing potential must employ effective contraception during the radiation therapy.
- A radiation planning CT scan which demonstrates a target lumpectomy cavity that is not clearly delineated or a target lumpectomy cavity/whole breast reference volume > 30%.
- Unacceptable radiation therapy quality assurance parameters, as defined in Section 5 of the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Partial breast radiation after lumpectomy
Radiation per NSABP B-39/R0413 protocol.
|
Radiation therapy will be administered in the vicinity of the center where the surgical resection was performed.
Adjuvant radiation must start within 12 weeks of breast excision or re-excision.
The radiation oncologist can choose between two methods of partial breast irradiation (PBI): external beam partial breast radiation or Mammosite® brachytherapy, based on radiation oncologist and patient preference.
Radiation will be administered per guidelines used in the NSABP B-39/RTOG 0413 protocol.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Participants With Local Recurrence up to 10 Years
Time Frame: up to 10 years
|
The primary objective is to determine the local recurrence rate for patients with borderline or malignant phyllodes tumors treated with breast conserving resection with negative margins and adjuvant partial breast radiation therapy.
Recurrence rate is measured by occurrence of biopsy proven recurrences during follow up, up to 10 years following patient enrollment.
|
up to 10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Participants With Local Recurrence After Radiation Compared to Historic Controls
Time Frame: up to 10 years
|
The secondary objective is to compare the local recurrence rate observed after partial breast radiation therapy with that observed in historical controls treated with whole breast radiation therapy after breast conserving resection with negative margins.
This is measured by occurrence of biopsy proven recurrence up to 10 years after participant enrollment.
|
up to 10 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Richard J Barth, JR, MD, Dartmouth-Hitchcock Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D0929
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Phyllodes Tumor
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversitySun Yat-sen University; The Third Affiliated Hospital of Guangzhou Medical... and other collaboratorsRecruitingArtificial Intelligence | Diagnosis | Phyllodes Breast Tumor | Multiomics | Prognostic Cancer ModelChina
-
KK Women's and Children's HospitalRecruiting
-
Kasr El Aini HospitalCompletedBreastcancer | Phyllodes Breast TumorEgypt
-
Dartmouth-Hitchcock Medical CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Lawson Health Research InstituteNot yet recruitingBreast Fibroadenoma | Lobular Carcinoma in Situ | Atypical Ductal Hyperplasia | Phyllodes Breast Tumor | Atypical Lobular Hyperplasia | Flat Epithelial Atypia | Phyllodes; Fibroadenoma | Radial Scar | Breast Papilloma | Complex Sclerosing Papillary Lesion of the Breast
-
Baylor College of MedicineCancer Prevention Research Institute of Texas; The Methodist Hospital Research... and other collaboratorsActive, not recruitingRefractory Neuroblastoma | Uveal Melanoma | Relapsed Ewing Sarcoma | Relapsed Osteosarcoma | Relapsed Neuroblastoma | Relapsed Rhabdomyosarcoma | Phyllodes Breast TumorUnited States
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
Clinical Trials on Partial breast radiation after lumpectomy
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingAnatomic Stage 0 Breast Cancer AJCC v8 | Prognostic Stage 0 Breast Cancer AJCC v8 | Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Bilateral Breast CarcinomaUnited States
-
Stanford UniversityNational Cancer Institute (NCI)Withdrawn
-
Stanford UniversityRecruitingSurgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma (NORDIS)Ductal Breast Carcinoma in SituUnited States
-
Wake Forest University Health SciencesAtrium Health NavicentActive, not recruitingBreast Cancer Female | Early-stage Breast CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingStage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast CancerUnited States, Canada
-
Xoft, Inc.CompletedCarcinoma | Breast Cancer | Ductal Carcinoma in Situ | LumpectomyUnited States
-
Weill Medical College of Cornell UniversityRecruitingBreast CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAnatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma | Estrogen Receptor-Positive Breast CarcinomaUnited States
-
King Abdulaziz UniversityCompletedBreast Cancer | Breast Neoplasms | Breast Cancer FemaleSaudi Arabia
-
UNICANCERActive, not recruitingBreast Cancer | LumpectomyFrance